BiBLDR: Bidirectional Behavior Learning for Drug Repositioning
This work addresses drug repositioning for pharmaceutical research to reduce development costs, with a focus on improving performance in cold-start scenarios, representing an incremental advance over existing graph-based methods.
The paper tackles the problem of drug repositioning in cold-start scenarios where novel drugs lack association information with diseases by proposing BiBLDR, a bidirectional behavior learning framework that redefines the task as behavior sequential learning; it achieves state-of-the-art performance on benchmark datasets and shows significantly superior results in cold-start cases.
Drug repositioning aims to identify potential new indications for existing drugs to reduce the time and financial costs associated with developing new drugs. Most existing deep learning-based drug repositioning methods predominantly utilize graph-based representations. However, graph-based drug repositioning methods struggle to perform effective inference in cold-start scenarios involving novel drugs because of the lack of association information with the diseases. Unlike traditional graph-based approaches, we propose a bidirectional behavior learning strategy for drug repositioning, known as BiBLDR. This innovative framework redefines drug repositioning as a behavior sequential learning task to capture drug-disease interaction patterns. First, we construct bidirectional behavioral sequences based on drug and disease sides. The consideration of bidirectional information ensures a more meticulous and rigorous characterization of the behavioral sequences. Subsequently, we propose a two-stage strategy for drug repositioning. In the first stage, we construct prototype spaces to characterize the representational attributes of drugs and diseases. In the second stage, these refined prototypes and bidirectional behavior sequence data are leveraged to predict potential drug-disease associations. Based on this learning approach, the model can more robustly and precisely capture the interactive relationships between drug and disease features from bidirectional behavioral sequences. Extensive experiments demonstrate that our method achieves state-of-the-art performance on benchmark datasets. Meanwhile, BiBLDR demonstrates significantly superior performance compared to previous methods in cold-start scenarios. Our code is published in https://github.com/Renyeeah/BiBLDR.